lasmiditan (Reyvow)
Jump to navigation
Jump to search
Indications
Contraindications
- not indicated for prevention of migraine
- second dose not effective foor same migraine
- not recommended for Child-Pugh class C cirrhosis
Dosage
* not to exceed 1 dose/24 hours
Dosage adjustment in renal failure
- none
Adverse effects
- minimal cardiovascular effects
- sleepiness, dizziness, fatigue, paresthesia, sedation, muscle weakness
- impaired driving (8 hr between dosing & driving or operating machinery)
- nausea (lumped with neurological adverse effects[3])
Mechanism of action
- serotonin agonist selective for the 5-HT1F receptor
Notes
- phase III trials June 2018
More general terms
References
- ↑ Highleyman L. Lasmiditan Provides Rapid Migraine Relief. First-in-class drug promises efficacy without cardiovascular side effects. MedPage Today. July 02, 2018 https://www.medpagetoday.com/meetingcoverage/ahs/73804
Wietecha L, et al Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine. American Headache Society (AHS) 2018; Abstract IOR-02.
Maassen van den Brink A, et al Lasmiditan inhibits CGRP release in the mouse trigeminovascular system. American Headache Society (AHS) 2018; Abstract OR-03. - ↑ FDA News Release. Oct 11, 2019 FDA approves new treatment for patients with migraine https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine
- ↑ 3.0 3.1 Windle ML Rapid Rx Quiz: Headache Medications Medscape. Sept 12, 2022 https://reference.medscape.com/viewarticle/980181
- ↑ Medscape: lasmiditan (Rx) https://reference.medscape.com/drug/reyvow-lasmiditan-1000310